Poviral

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Poviral

Understanding Poviral

Poviral is a medicinal product categorized as an antiviral agent. It is primarily used in the management of infections caused by certain types of viruses, specifically those within the herpesvirus family. The active substance in this medication is aciclovir, a synthetic purine nucleoside analogue.

Mechanism of Action

The medication works by interfering with the replication process of the viral DNA. Once Poviral enters a virus-infected cell, it undergoes a chemical conversion into an active form. This active component then acts as a substitute for the natural building blocks of DNA, effectively halting the chain synthesis of the viral genetic material. Because the medication requires a specific viral enzyme to become fully active, it primarily targets infected cells while having a limited impact on healthy, uninfected cells.

Primary Uses

Poviral is utilized for several conditions related to viral activity:

  • Herpes Simplex Infections: It is used to treat infections of the skin and mucous membranes, including initial and recurrent episodes of genital herpes.
  • Varicella-Zoster Virus: The medication is employed in the treatment of shingles (herpes zoster) and chickenpox (varicella).
  • Suppression and Prevention: In individuals with a high frequency of recurrence, it may be used as a suppressive therapy to reduce the number of outbreaks. It is also used prophylactically in patients with compromised immune systems to prevent viral reactivation.

While Poviral helps manage the symptoms and duration of these infections, it is important to note that it does not provide a permanent cure for herpesvirus infections, as the virus remains dormant in the body even when symptoms are not present.

Regulatory References

  1. Acyclovir: MedlinePlus Drug Information
  2. Aciclovir - WHO EML

What side effects are possible with Poviral?

Adverse Reactions and Safety Information

Poviral (Acyclovir) cream is primarily associated with local application site reactions due to its minimal systemic absorption. Safety data is based on regulatory documentation and controlled clinical trials.

Documented Side Effects

Classification Adverse Reactions (Examples)
Common (Reported by 1% to 10% of patients) Local skin reactions at the application site, including transient stinging, mild burning, and itching.
Uncommon / Less Common Mild drying or flaking of the skin, erythema (redness), dry lips, cracked lips, and contact dermatitis.
Rare / Post-Marketing Immediate hypersensitivity reactions, including angioedema and urticaria (hives).

Safety and Restrictions

Serious Adverse Reactions (Systemic Exposure): While minimal systemic absorption is expected with topical use, more serious risks are documented with systemic (oral or intravenous) acyclovir administration. These include encephalopathic changes (such as confusion, lethargy, tremors, and seizures) and renal precipitation, the latter being associated with rapid intravenous infusion.

Application Restrictions: Poviral is intended for cutaneous use only on the external affected areas of the lips and face. Application to human mucous membranes, including the eye or the inside of the mouth or nose, is not recommended due to the potential for irritation and contact sensitization.

Specific Populations: The low systemic exposure of the topical cream suggests maternal use is not expected to result in fetal or infant exposure during pregnancy or lactation, though use should be considered in the context of potential benefits versus unknown risks.

Overdose and Emergency Response

The official regulatory documents establish the overdose profile of Poviral (Aciclovir) based on documented findings, primary toxicities, and mandated emergency procedures.

Documented Manifestations and Severe Outcomes

System Clinical Presentation Severe Outcome
Gastrointestinal Nausea and vomiting (with repeated oral overdose).
Central Nervous System (CNS) Headache, confusion, hallucinations, and agitation. Seizures and coma are possible severe outcomes.
Renal Elevations of serum creatinine and blood urea nitrogen. Subsequent renal failure is documented, especially following IV overdosage.

Emergency Action and Official Management

Immediate medical attention is required for any symptomatic overdose. Regulatory labeling mandates that patients must be placed under close observation for signs of toxicity and receive symptomatic and supportive treatment.

While no specific antidote is described in official documents, haemodialysis is documented as a management option because it significantly enhances the removal of the active substance from the blood. The official profile highlights that the risk of neurological side effects is increased in elderly patients and individuals with existing renal impairment. The risk of systemic overdose with topical formulations is cited as unlikely due to minimal absorption.

Therapeutic Uses of Poviral

What Poviral Treats: Main Uses and Benefits

Poviral is a medicine whose therapeutic domain is primarily applied across domains where additional symptomatic support is needed. This medication is commonly used across these domains, specifically applied in addressing conditions involving inflammatory or irritative processes. The active ingredient in Poviral is used for managing symptom clusters that may become intense or disruptive associated with certain viral infections.

This medication is generally relevant for easing conditions involving episodic or fluctuating manifestations, such as outbreaks of shingles, chickenpox, and various forms of herpes simplex (including genital herpes and cold sores). Management, often used during phases when symptoms become more noticeable, provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load. Additionally, it may assist with maintaining functional stability in situations where patients experience recurrent episodes. This helps maintain a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases.

Supportive Benefit: Helps with Symptoms that Interfere with Daily Functioning.

Regulatory References

  1. Acyclovir: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Poviral?

The official regulatory documentation for Poviral (Acyclovir) defines specific populations for use and exclusion based on hypersensitivity, age, immune status, and the type of formulation.

Exclusion (Contraindicated) Populations

Poviral is formally contraindicated in individuals with a known hypersensitivity or allergic reaction to the active substance Acyclovir, its related compound Valacyclovir, or any other ingredient (excipient) present in the specific formulation.

Eligibility Restrictions

Domain Restriction/Limitation
Age Profile Topical cream is typically restricted to use in adults and adolescents ge 12 years of age; safety is not established for younger pediatric patients.
Immune Status The topical cream formulation is not recommended for the treatment of cold sores in immunocompromised patients due to potentially limited effectiveness or the need for systemic treatment.
Route of Use Topical formulations are restricted to external skin use only. They must not be applied to mucous membranes (e.g., inside the mouth, nose, or vagina) or to the eye.
Physiological Status Use during pregnancy or lactation is generally not recommended unless the prescribing physician determines that the potential benefit outweighs any potential risk to the fetus or infant. Renal impairment requires caution and potential dosage adjustment for systemic forms.

These constraints establish the official regulatory scope for who may be eligible to use the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Interactions with Poviral (Aciclovir) are primarily governed by the competition for active renal tubular secretion, which is the main route for the medicine's elimination. Specific co-administered medicines that interfere with this process can lead to clinically significant exposure modification.

Official Interaction Statements

  • Probenecid and Cimetidine both increase Aciclovir plasma concentrations and reduce its renal clearance. This outcome is attributed to competitive inhibition of the medicine's removal from the body via renal transporters.
  • Co-administration with Mycophenolate Mofetil has been documented to result in an increase in the plasma concentration of Aciclovir.
  • Poviral may officially increase the serum concentrations of Theophylline.
  • Official regulatory cautions exist regarding additive organ toxicity risk: co-administration with other potentially nephrotoxic agents may increase the risk of renal dysfunction.
  • The use of intravenous Poviral requires patients to maintain adequate hydration to reduce the physical risk of renal tubular damage tied to the elimination process.

Population-Specific Notes

Geriatric patients and patients with pre-existing renal impairment are at a higher risk for toxicity from interactions that increase systemic exposure, as their natural clearance rates are often reduced.

Food and Substance Interactions

No known interaction with food is documented in regulatory prescribing information, and the medicine may be taken independently of meals.

Mechanism of Action

Poviral's mechanism of action is defined by a process that is highly selective based on viral enzyme presence, interfering directly and fundamentally with the viral replication cycle. This activity is restricted to two main mechanistic domains: enzyme-driven activation and permanent genetic interference.

Viral-Selective Activation by Enzyme Targeting

The active ingredient, Aciclovir, acts as a prodrug that is only converted into its active form by the Viral Thymidine Kinase, an enzyme unique to the target virus. This reliance on the viral enzyme ensures the drug is predominantly activated and concentrated inside the infected cell, resulting in preferential concentration of the active triphosphate form within the infected cell, which limits systemic interaction with non-infected host cells.

Obligate Termination of Viral DNA Synthesis

Once fully activated, the drug functions as a nucleoside analogue that competitively inhibits the Viral DNA Polymerase enzyme. When this faulty analogue is incorporated into the growing viral DNA strand, the chain reaction of synthesis is instantly and permanently halted (chain termination). This profound physiological change stops the production of new viral particles. This cessation of genetic material synthesis restricts the subsequent cellular process of virion assembly and release.

Mechanistic Constraints and Latent Virus

Since the drug requires the presence of the viral enzyme associated with active replication, its mechanism of action is limited to targeting this stage. It does not possess a mechanism to target the latent (dormant) viral DNA residing within host cells, confirming the limitation to active replication only.

Dosage and Administration Information

How to Use Poviral

Poviral (Aciclovir) is administered through specific routes and dosing schedules based on the required systemic or localized action. The medicine is available for oral use (tablets, capsules, suspension), intravenous (IV) infusion (powder for solution), and topical application (cream, ophthalmic ointment).

Oral forms may be taken with or without food. Dosing frequency is highly dependent on the condition, ranging from twice daily for long-term suppressive use to five times daily for acute treatment, such as for Herpes Zoster. Treatment courses are generally short-term, lasting 5 to 10 days.

Administration Route Procedural Principle Frequency / Duration
Oral (Systemic) May be taken with or without food. Typically 2 to 5 times daily; 5 to 10 days duration.
IV Infusion Must be given as a slow infusion over at least one hour. Usually 3 times daily (every 8 hours); 5 to 7 days duration.
Topical Applied directly to the affected area. Multiple times per day for a localized period.

The intravenous solution is a critical-use form that must be properly reconstituted and diluted to a concentration not exceeding 5 mg/mL and must not be given as a rapid or bolus injection. To protect kidney function, patients receiving systemic treatment must maintain adequate hydration. Dose adjustment is a mandatory procedural constraint for patients with renal impairment, where the dose must be reduced based on creatinine clearance. If a dose is missed, it should be taken as soon as possible, unless the next dose is due, in which case the missed dose must be skipped. Double doses are prohibited.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Poviral

Evidence for use in Recurrent Herpes Labialis (Cold Sores)

The research exploring Poviral for cold sores primarily involves short-term Randomized Controlled Trials (RCTs). These studies evaluated both oral and topical formulations in otherwise healthy adults and adolescents. Research examined outcomes linked to inflammatory states, focusing on the duration of the episode and the time until the lesion crusted over. Findings were mixed when comparing some topical applications to placebo, and evidence quality varies across studies, particularly given the fast natural healing process of cold sores. Follow-up durations were limited, as the research primarily explored short-term symptom changes related to the acute episode itself.

Evidence for use in Genital Herpes Simplex Virus (HSV) Infection

The evidence for managing genital HSV infection is drawn from short-term RCTs for acute episodes and longer-term trials for preventing recurrences (suppressive therapy). Studies monitored outcomes such as the duration of symptoms and the time until the lesions healed. For suppressive therapy, studies examined group patterns related to the frequency of outbreaks and the duration of viral shedding over observation periods lasting up to a year or more. Studies monitoring the rate of recurrence described patterns related to the frequency of subsequent episodes. However, long-term effects are not fully established regarding the use of suppressive therapy for many years.

Evidence for use in Herpes Zoster (Shingles) and Varicella (Chickenpox)

Research explored the use of Poviral in both shingles and chickenpox infections. For shingles, RCTs was evaluated specifically tracking the rate of skin lesion healing and the severity of acute pain. Crucially, research also monitored endpoints related to Postherpetic Neuralgia (PHN), a complication involving persistent pain. The evidence for chickenpox largely stems from studies conducted before the routine use of the varicella vaccine. Therefore, results apply only to the populations studied under those specific historical circumstances. Comparative evidence against newer antiviral agents remains an area where data are limited.

Key Studies & References

  1. Acyclovir: MedlinePlus Drug Information (Authoritative overview of uses, dosing, and side effects)
  2. WHO Model List of Essential Medicines - Aciclovir (Regulatory status and essential medicine context)

Frequently Asked Questions (FAQ)

Common questions about Poviral (FAQ)


Q: Is it normal to feel tired when starting Poviral?

Regulatory documents for oral Poviral (Aciclovir) list fatigue (feeling tired) as a commonly reported side effect. Because Poviral can sometimes affect the central nervous system (CNS), other related symptoms like sleepiness have also been reported.


Q: Why do some people experience stomach issues with Poviral?

Stomach issues are frequently reported with oral formulations of Poviral. Official product information states that common adverse reactions include nausea, vomiting, diarrhea, and stomach pain.


Q: Does Poviral cause dry mouth or changes in taste?

Regulatory documents indicate that taste disturbances are a possible side effect of Poviral (Aciclovir). However, dry mouth is not explicitly listed as a common adverse reaction in the official product information.


Q: Can Poviral affect my sleep schedule?

Official documentation reports that both insomnia (difficulty sleeping) and somnolence (sleepiness) are reported side effects of systemic Poviral. This indicates a potential for the medicine to influence sleep or wakefulness.


Q: Is there a best time of day to take Poviral?

The key principle for Poviral dosing is maintaining a consistent antiviral level in the body. Treatment is focused on taking the drug at regular intervals (e.g., every four hours) rather than a specific time of day like morning or evening. It is important to follow the precise dosing schedule prescribed for the condition.


Q: Are there any specific supplements that interact with Poviral?

While regulatory sources specify known interactions with certain prescription medicines, most supplements are not routinely tested for interaction. General health guidance emphasizes the importance of informing a healthcare provider about all medicines, including supplements, vitamins, and herbal products, as they may not have been formally studied for interaction.


Q: Can Poviral make me feel dizzy or lightheaded?

Yes, dizziness is listed as a commonly reported side effect in the official safety information for Poviral (Aciclovir). This is typically associated with the oral formulations of the medicine.


Q: Is Poviral generally well-tolerated by most patients?

Official safety data indicates that while many side effects are reported, the most common reactions are often temporary and mild. Side effects, when they occur, are often reported as temporary and may resolve after discontinuation of the medicine or after a short period.


Q: Does Poviral require any special monitoring while taking it?

Regulatory documents indicate that caution and appropriate clinical monitoring of kidney function are often necessary for populations such as those with existing renal impairment or those co-administering other potentially nephrotoxic agents. This monitoring is required for systemic use (oral or intravenous).


Q: How does Poviral affect the immune system?

Poviral (Aciclovir) is highly selective and acts primarily by targeting an enzyme unique to the virus itself, inhibiting the virus's ability to replicate. The mechanism of action is focused on disrupting the viral life cycle and does not involve a direct effect on the host's overall immune system cells.


Q: Will Poviral affect the results of lab tests?

Official adverse reaction reports indicate that Poviral can potentially increase levels of blood urea nitrogen (BUN) and creatinine. These are specific lab values that doctors monitor to assess kidney function.


Q: How does the body eliminate Poviral after it is taken?

Pharmacokinetic data confirms that the majority of Poviral is eliminated through the kidneys. It is primarily excreted in the urine as the unchanged drug, following glomerular filtration and tubular secretion.

How should Poviral be stored and disposed of?

Storage and Disposal Requirements for Poviral (Aciclovir)

Poviral must be stored according to regulatory specifications to ensure its stability. Tablets and capsules should be kept at Controlled Room Temperature, typically below 25 C (77 F), and must be protected from moisture and light in the original container.

Specific handling rules apply to the oral suspension: it must not be refrigerated or frozen to prevent crystallization. Once the suspension is opened, it must be discarded after 28 to 30 days.

All forms of this medicine must be kept out of the sight and reach of children.

For disposal, unused or expired Poviral should not be thrown into household waste or flushed into wastewater. It must be returned to a pharmacy or designated collection point as required by local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Poviral found in:

A-Z Index: